-
Mashup Score: 2
Neoadjuvant cisplatin-based chemotherapy is associated with pathologic complete response (pCR) in muscle-invasive bladder at the time of cystectomy for a proportion of patients with muscle-invasive bladder cancer (MIBC). Patients with a pCR have improved overall survival relative to patients with no pCR. A challenge in the treatment of patients with MIBC is identifying patients that may be able…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2
In this conversation with Alicia Morgans, MD, MPH, Arjun Balar, MD highlights a multicenter study first designed in 2014 of gemcitabine hypofractionated radiation therapy and pembrolizumab all in combination as bladder-sparing therapy for patients with muscle-invasive bladder cancer that had a total of 54 patients. The goal of the study was to test the role of immunotherapy pembrolizumab added…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1
ASCO 2021 forgoing radical cystectomy with upfront transurethral resection of bladder tumor (TURBT) and neoadjuvant chemotherapy and avoid the morbidity of surgery, DNA damage alterations, MVAC chemotherapy.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1
HCRN GU 16–257, cisplatin-based chemotherapy plus PD-1 blockade refine a TURBT plus systemic therapy for bladder cancer, Bladder Sparing in Patients With Muscle-Invasive Bladder Cancer, phase 2 trial HCRN GU 16-257 assessing gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
Phase 2 trial of gemcitabine, cisplatin, + nivolumab with selective #BladderSparing in patients with muscle-invasive #BladderCancer: HCRN GU 16–257. Presentation by @MattGalsky @TischCancer. #ASCO21 written coverage by @zklaassen_md > https://t.co/Kz8C2TM5XT @ASCO @siadaneshmand https://t.co/x6o56LuU2V
-
-
Mashup Score: 7
phase 2 trial evaluating the safety and efficacy of pembrolizumab added to trimodality bladder preservation therapy in muscle-invasive bladder cancer. Curative intent therapy in muscle-invasive bladder cancer, neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy, trimodality bladder preservation therapy, standard treatment option for clinically localized muscle-invasive bladder…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy as #BladderSparing treatment for muscle-invasive #BladderCancer. Presentation by @ArjunBalarMD @nyulangone. #ASCO21 written coverage by @zklaassen_md > https://t.co/UIe4cusLh6 @ASCO https://t.co/JNUwohbKFz
-
HCRN GU 16-257 a phase 2 trial of gemcitabine, cisplatin, + nivolumab shows promise for #BladderSparing in muscle-invasive #BladderCancer. @MattGalsky @TischCancer joins @CaPsurvivorship @NUFeinbergMed highlighting data presented at #ASCO21. #WatchNow > https://t.co/5lvX7ypFNt https://t.co/R8Q9VTAJ5F